The new drug, Latuda (lurasidone), will compete in a crowded market of "atypical" antipsychotics (Zyprexa, Abilify, Invega, etc)

The new drug, Latuda (lurasidone), will compete in a crowded market of "atypical" antipsychotics (Zyprexa, Abilify, Invega, etc).

Atypicals are used to treat conditions such as psychosis or schizophrenia. Latuda is now the TENTH oral atypical antipsychotic.

More money is spent on antipsychotics than any other class.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote